![]() | ![]() |
Formats:
|
||||||||
Copyright © 2008 Ludwig; licensee BioMed Central Ltd. RNA silencing and HIV: A hypothesis for the etiology of the severe combined immunodeficiency induced by the virus 1861 Main Street, East Aurora, New York, 14052, USA Corresponding author.Linda B Ludwig: linda.b.ludwig/at/gmail.com Received February 27, 2008; Accepted September 11, 2008. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract A novel intrinsic HIV-1 antisense gene was previously described with RNA initiating from the region of an HIV-1 antisense initiator promoter element (HIVaINR). The antisense RNA is exactly complementary to HIV-1 sense RNA and capable of forming ~400 base-pair (bp) duplex RNA in the region of the long terminal repeat (LTR) spanning the beginning portion of TAR in the repeat (R) region and extending through the U3 region. Duplex or double-stranded RNA of several hundred nucleotides in length is a key initiating element of RNA interference (RNAi) in several species. This HIVaINR antisense RNA is also capable of forming multiple stem-loop or hairpin-like secondary structures by M-fold analysis, with at least one that perfectly fits the criteria for a microRNA (miRNA) precursor. MicroRNAs (miRNAs) interact in a sequence-specific manner with target messenger RNAs (mRNAs) to induce either cleavage of the message or impede translation. Human mRNA targets of the predicted HIVaINR antisense RNA (HAA) microRNAs include mRNA for the human interleukin-2 receptor gamma chain (IL-2RG), also called the common gamma (γc) receptor chain, because it is an integral part of 6 receptors mediating interleukin signalling (IL-2R, IL-4R, IL-7R, IL-9R, IL-15R and IL-21R). Other potential human mRNA targets include interleukin-15 (IL-15) mRNA, the fragile × mental retardation protein (FMRP) mRNA, and the IL-1 receptor-associated kinase 1 (IRAK1) mRNA, amongst others. Thus the proposed intrinsic HIVaINR antisense RNA microRNAs (HAAmiRNAs) of the human immunodeficiency virus form complementary targets with mRNAs of a key human gene in adaptive immunity, the IL-2Rγc, in which genetic defects are known to cause an X-linked severe combined immunodeficiency syndrome (X-SCID), as well as mRNAs of genes important in innate immunity. A new model of intrinsic RNA silencing induced by the HIVaINR antisense RNA in the absence of Tat is proposed, with elements suggestive of both small interfering RNA (siRNA) and miRNA. Background In life, timing is everything. Developmental transitions must be exquisitely and appropriately timed, for an animal to develop normally. Genes have to know when to turn on and when to turn off. Proteins need to be translated efficiently when (and where) they will do the most good. Two early examples of a unique form of regulation of gene expression by RNA instead of the more usual protein were mediated by the 22-nucleotide lin-4 RNA[1,2] and the 21-nucleotide (nt) let-7 RNA [3]. These small RNAs were found to regulate the timing of development in the roundworm, the nematode Caenorhabditis elegans [1,4,5]. The lin-4 22 nt and 61 nt precursor were noted to have antisense complementarity to several sites in the lin-14 gene, in sites already known to be important in mediating repression of lin-14 [1,2]. Each final, small RNA is processed from larger RNAs and is very specific in its action because it is complementary to sequences in the 3' untranslated regions (3'UTR) of a specific set of mRNAs of protein-coding target genes [1-3,5,6]. Remarkably, the 21 nt RNA encoded by the let-7 gene appears to be conserved across species, from the original roundworms and molluscs to drosophila and to vertebrates, including humans [4]. Recently, these tiny RNAs or microRNAs (miRNAs) have been shown to regulate a wide range of biological processes besides developmental timing, including apoptosis, differentiation, hormone secretion, and even cancer (reviewed in [7-11]. It has also been proposed that small RNAs may play important roles in the host-pathogen interaction: both by mammalian cells to defend against viral infections, and by some viruses, in turn, to escape or adapt to RNA silencing [12]. In the human immunodeficiency virus (HIV-1), the virus has already "borrowed" known transcription factor binding sites and enhancer elements (NFAT, NFkB, Tata box, Sp1 sites) to enable it to effectively utilize the human host cell proteins and RNA polymerase in transcription of its mRNAs and genomic RNA[13]. It is perhaps not surprising that it would also make an antisense RNA to enable a mechanism for fine-tuning the timing of final translational expression of its genes [14]. It would be extremely inefficient to make proteins required for the complete virion if conditions in the cell are suboptimal. In the absence of Tat protein, one of the early regulatory proteins made by the virus, short transcripts of approximately 55–60 nt are predominantly observed [15]. Some early experiments even suggested negative regulatory elements or an inducer of short transcripts to maintain the virus in latency, as when the human host cell was not activated [16]. More recent papers have suggested that the trans-activation-response region (TAR) of HIV-1 mRNA, present in all sense HIV-1 transcripts, functions as a microRNA precursor [17,18]. This paper explores the possibility that HIV-1 might incorporate two mechanisms for RNA silencing that contribute to maintenance of a quiescent state in the host cell, in the absence of Tat protein. It was previously shown that the antisense RNA originating from the region of the HIV antisense initiator (HIVaINR) promoter element is produced simultaneously along with the sense transcripts [14]. This HIVaINR antisense RNA forms an intrinsic bimolecular duplex with U3R sense mRNA (at the 3' end of HIV genomic RNA or mRNA) and suggests the capacity for RNA interference (RNAi). The RNAi pathway begins with long double-stranded RNA, which are naturally generated within the host cell from both HIV-1 sense and antisense transcripts [14]. HIVaINR antisense RNA begins off a site in the R region and extends through the U3 region with perfect complementarity but opposite polarity to its template sense DNA U3R strand. It would therefore have perfect complementarity to any sense HIV mRNA consisting of 3' U3R sequence. It also would have perfect complementarity to the beginning region of all HIV-1 sense mRNAs at the 5'R or TAR region, forming a 25 bp duplex as previously described [14]. In the RNAi pathway, double-stranded RNA is processed by Dicer and then unwound into many ≈22 nt small interfering RNAs (siRNAs), with one strand of the duplex small RNA incorporated into a ribonucleoprotein complex called the RNA-induced silencing complex (RISC) [19-22]. Complementary base-pairing between the siRNA incorporated into the RISC and the mRNA determines the targeted mRNA sites, with cleavage of the mRNA directed between the nucleotides pairing to residues 10 and 11 of the siRNA [23,24]. In HIV-1, the siRNAs would be capable of targeting multiple intrinsic sites on HIV mRNAs because of the extensive perfect complementarity of an intrinsically produced HIVaINR antisense RNA. The converse may also be true, inasmuch as the sense strand of the siRNA duplex could also be targeting the HIVaINR antisense RNA. However, the HIVaINR antisense RNA itself also has extensive secondary structure and is capable of forming intramolecular duplex structures or extended hairpins (discussed below). Some of these intrinsic HIVaINR antisense RNA hairpins fit criteria for a microRNA precursor. Thus, a second mechanism employed by the virus for gene silencing may involve the microRNA (miRNA) pathway utilizing this HIVaINR antisense RNA, which will be explored below. Because of the human gene mRNAs also potentially targeted, this may represent intrinsic mechanisms for (self) viral and human host gene regulation by the HIV-1 virus. In the process, the HIV-1 targeting of specific human genes may have profound effects on the human host adaptive and innate immunity. Results and Discussion Could the HIVaINR antisense gene encode its own microRNA subspecies? The capacity for an intrinsic RNA regulatory mechanism for control of HIV-1 gene expression by means of an antisense RNA initiated from the HIVaINR in TAR (LTR) DNA has been suggested previously [14]. This antisense RNA most notably has the capacity to form a duplex of 25 bp with the 5' end of all sense HIV mRNA and genomic HIV-1 RNA (see additional file 3 (figure 3S) in [14]). At the time this was initially proposed in 1996, the known models for duplex RNAs regulating genes were in prokaryotes [25,26]; the term "microRNA" would not be coined until 2001 [6,27,28]. However, this same HIVaINR antisense RNA which encodes antisense proteins (HAPs), also has the capacity to form hairpin structures that could be precursors to the formation of intrinsic viral microRNAs (vmiRNAs) named the HIVaINR antisense RNA miRNAs or HAAmiRNAs [14]. Others have suggested the possibility for HIV microRNAs encoded by the sense strand of HIV mRNAs with the potential for an entirely different set of human cellular target mRNAs[17,18,29,30]. HIVaINR antisense RNA forms extensive intrinsic duplex structure by M-fold analysis and DINAMelt server (see Figure Figure11 While folding free energy and stem length were not sufficient to discrimate miRNA precursors from other long RNA duplexes, it was determined by computational analysis that nonprecursor duplexes differed from real miRNA precursors in having increased lengths and numbers of bulges and internal loops and larger apical loop size [38]. These secondary structure characteristics were utilized in developing a miRNA prediction algorithm, with comparisons done using the RNAforester tool [42,43]. When the HIVaINR antisense RNA sequence from nt 168–253 [14] was submitted to this structure-based miRNA analysis tool for analysis, it received a perfect score (100) consistent with this sequence being a microRNA precursor (Ritchie et al, http://tagc.univ-mrs.fr/mirna/) [38]. Further comparison with the M-fold duplexes demonstrated that even with the 390 nucleotide HIVaINR antisense RNA [14] subjected to enhanced M-fold, some of the structures could potentially be processed (first by Drosha, then Dicer) into this final pre-miRNA (see additional file 1, structure with folding energy dG = -96.7). This was important, inasmuch as the HIVaINR antisense RNA stem-loop also contained 25 bases that could in turn form yet another duplex or target with several human mRNAs. Two of the many mRNAs targeted included mRNA of the human gene, interleukin-2 receptor gamma chain (IL-2Rγc), a gene in which defects are responsible for X-linked severe combined immuno-deficiency (X-SCID), as well as the human interleukin-15 mRNA, discussed below (diagrammed in Figure 2A, B, E
Human interleukin-15 mRNA: a proposed target of the HIVaINR antisense RNA site 1 (HAAmiRNA 1, *1) HIVaINR antisense RNA sequence from nt 168–253 [14] is capable of forming a stem-loop or hairpin structure consistent with a precursor miRNA (Figure (Figure11 Figure Figure2B2B Interleukin-15 is a cytokine that is important in regulation of T-cell maturation and natural killer (NK) cell development and that is secreted by human macrophages and other cells [50-54]. Interleukin-15 and interleukin-7 are required for survival of long-lived memory T cells [50,55]. Studies in mice and humans suggest that a functional IL-15/IL-15 receptor signalling pathway is required for development and survival of NK cells [50-52,54]. NK cells are a class of lymphoid cells that contribute to innate host defense against intracellular pathogens and viruses, as well as tumor cells[54]. The IL-15 receptor consists of a unique IL-15Rα chain that combines with two other receptor chains that are also shared with the IL-2 receptor, the β and γc subunits. HAAmiRNA 1 also potentially targets the γc subunit or IL-2Rgamma chain mRNA (discussed below). The combined effects of HIV-1 microRNA action to inhibit protein production from these mRNAs would be predicted to impact on natural killer cell function. Because NK cell activity represents one of the early host innate immune responses against virally infected cells, HIV-1 could thereby strike an early and crippling blow against the human immune response. Interleukin-2 receptor gamma chain (common gamma chain) (γC)- a proposed human mRNA target of the HIVaINR antisense RNA site 1 (HAAmiRNA 1, 1*) The HIVaINR antisense RNA stem-loop precursor (HAAmiRNA 1,1*) also contains sequence that can form duplex structures with several sites on mRNA encoding the interleukin-2 receptor gamma chain (IL-2RG). IL-2RG is now known as the common gamma (γc) cytokine receptor chain because it is a component of the interleukin receptors IL-2R, IL- 4R, IL-7R, IL-9R, IL- 15R, and IL-21R [56-59]. Genetic defects or mutations in IL-2RG (γc) gene can cause X-linked severe combined immunodeficiency (X-SCID) secondary to the profound T cell and NK cell deficiency induced by lack of a functional γc gene [60-62] X-linked SCID is so severe that some children who inherit it can only survive following bone marrow transplantation or in a pathogen-free environment, as demonstrated by the Houston child, the "boy in the bubble". HAAmiRNA 1 from nt 225–250[14] is involved in extensive complementary base-pairing to several sites in the 3' UTR of IL-2RG mRNA as well as to sites in intronic and 5' regions of the IL-2RG mRNA (Figure (Figure2A,2A If the human immunodeficiency virus wanted to turn off T-cell proliferation to enable it to subvert the cell's machinery for other purposes, IL-2RG chain (γc) would be the perfect switch The adaptive immune response requires appropriate co-signals and cytokine stimulation for the T cell to proliferate in response to recognition of a specific antigen. This is one of the defining aspects of adaptive immunity: the capacity to greatly expand the population of T-cells (or B cells) that specifically recognize a foreign antigen and thereby bring an infection under control. Central to this pathway activating lymphocyte proliferation and, paradoxically, lymphocyte death is an autocrine (and paracrine) loop involving interleukin-2 and the tripartite interleukin-2 receptor complex, IL2-R[63]. The interleukin-2 receptor (IL2-R) and IL-15 R are heterotrimers that consist of a unique α-chain but share the IL-2R gamma (γ common or γc) chain and IL-2Rβ chain [59,63,64]. The receptors for the interleukins IL-4, IL-7, IL-9, and IL-21 are heterodimers with unique α-subunits and the shared subunit, IL-2RG or γc chain [56-58,64]. For all of these cytokine receptors, the γc chain contributes to ligand binding as well as signal transduction within the cell [54,64-66]. Targeting the human lymphoid cell IL-2Rgamma chain or γc mRNA by HAAmiRNA 1 could lead to multiple changes within the cell: impaired production of this receptor chain protein could alter or eliminate the human CD4+ T cells ability to proliferate and mount an effective adaptive immune response and also impair NK cell functioning via the IL-15R and IL-21R with an impact on innate immunity[56]. NK function also could be impacted by the absence of a critical cytokine, IL-15, discussed above. Mutation or gene deletion of the IL-2Rgamma chain (γc) in humans causes extremely low numbers of T cells, poor or absent T cell mitogen responses, severely depressed NK cell function, and an elevated or normal proportion of B cells that fail to produce specific antibodies[62]. Each of these defects are observable in the immune system of HIV-infected individuals, even before significant depletion of CD4+ T cells[67]. Even a single missense mutation in the γc chain can lead to a progressive T cell deficiency [68]. By analogy, one might expect the gradual accrual over time of a similar phenotype, as more human cells are infected by the virus and then incapacitated by viral microRNA translational inhibition (or cleavage) of the γc mRNA. Other HIVaINR antisense RNA predicted miRNAs? A variety of strategies were used to identify potential miRNA sites within the HIVaINR antisense RNA sequence [14]. First, the identification of potential microRNA precursor sites on the HIV-1 sense RNA strand immediately suggested similar structures were possible on the corresponding complementary antisense RNA that overlapped these regions [29,30] (diagrammed in additional file 2). This provided the impetus to look at sites encompassing HAAmiRNAs 1 and 3 (Figure 2A, 2B HIVaINR antisense RNA at site 2 between nucleotides 271–297 could potentially target mRNA sequence for human fragile × mental retardation protein (FMRP) (Figure (Figure1,1 This could be of major impact, if verified experimentally, because not only does the FMRP play a role in protein synthesis and bind large numbers of cellular mRNAs through G-quartet and U-rich motifs [69-72], but experimental evidence links FMRP with RISC components and miRNAs [73-75]. Mammalian FMRP interacts with miRNAs and Dicer and the mammalian orthologues of Argonaute (AGO) 1 [73,75]. Whether HAAmiRNA 2 targeting human mRNA for FMRP results in translational repression or cleavage of the human mRNA for FMRP, the effects will be amplified because of the large number of human mRNAs targeted by the FMRP protein itself. This would enable the virus to immediately impact on many hundreds of cellular messages. In addition, the primary RNAs for human microRNAs may be impacted, as has already been suggested for HIV-1-transfected human cells [30]. HIV potentially could thus use HAAmiRNA 2 to regulate the host effort to demolish the virus through host miRNA/siRNA silencing pathways. If HAAmiRNA 2 impedes efficient translation of FMRP, it also will affect FMRP interaction with proteins of the RNA-induced silencing complex. Others have already shown the importance of the two RNAase III enzymes fundamental to RNA silencing, Drosha and Dicer, in inhibiting HIV replication[76]. HIVaINR antisense RNA site 3 from nt 341–369 [14] (herein referred to as HAAmiRNA 3) could potentially target human mRNA for the interleukin-1 receptor-associated kinase 1 (IRAK1) (Figure (Figure11 It is of particular interest that human miR-146 has been shown to functionally interact with human mRNA 3'UTR sites for IRAK1 and thereby downregulate protein expression[77]. Expression of primary miR-146 transcripts is regulated by NF-kB sites, sites that are also important enhancer elements for expression of HIV-1 RNA transcripts [14,77,79]. IRAK1 is involved in the signalling cascade induced by activation of Toll-like receptors (TLRs) that are important in innate immunity. Experimental evidence that miR-146a/b may function as a novel negative regulator has been recently shown [77]. If HIV uses a microRNA mechanism like miR-146a to interact with IRAK1 mRNAs, which are expressed in macrophages and dendritic cells, it may provide yet another means for early viral impact on the host innate immunity pathways. RNA silencing by HIVaINR antisense RNA-a proposed model (Figure (Figure33 While RNA silencing triggered by double-stranded RNA [dsRNA] precursors occurs in a wide variety of eukaryotic organisms as a mechanism to regulate gene expression[22], early experiments in plants also suggested RNA silencing is employed as an antiviral mechanism to protect from RNA viruses [80-83]. To survive, viruses have had to evolve mechanisms to suppress or avoid the host RNA silencing response [83,84]. In this model, I propose that HIV-1 employs limited genetic space to best effect by producing a primary HIVaINR antisense RNA with multiple functions (Figure 3a–d The endogenous HIVaINR antisense RNA further has the intrinsic capacity for forming multiple dsRNA hairpin structures with complementary or near-complementary base-pairing (Figure (Figure11 Why would a virus utilize host cell enzymes Drosha and Dicer to dice up its own messages? Here, we must return to the initial concept of this paper, where timing of gene expression is so important to viral survival. The early skirmish in the battle between the virus and the host cell might require some sacrifice of intact viral messages for a time. By generating HAA miRNAs that incorporate into the host cell RISC, the virus can impede mRNAs from the host genes critical in enabling host innate as well as adaptive immune responses. The virus thereby employs the host's own anti-viral RNA silencing defence against the host cell. It can't be accidental that HAAmiRNA 1 has sequence that could target multiple complementary sites in human mRNA for the human IL-2R γ or common gamma (γc) chain, a requisite component in the receptors for all known T-cell growth factors (interleukins (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21). The same HAAmiRNA 1 sequence can also target multiple sites in the interleukin-15 mRNA, a key cytokine involved in NK cell functioning. In addition, until conditions are appropriate in the host cell for intact HIV RNA and protein production, dicing up the early transcripts (Figure (Figure3b)3b
Implications for HIV-1 vaccine development The particular HIV-1 genetic regions encompassing HAAmiRNA sites 1–3 are well conserved in the B clade, and even more remarkably, particularly conserve miRNA sequence required for mRNA target recognition in most of the clades of group M (A-D, F-H, J and K), with the exception of the O group strains (underlined, additional file 2)[106,107]. There is even conservation of a 7 nucleotide "seed" of the HAAmiRNA1 in some of the chimpanzee virus variants, CPZ.CAM 3 and 5 (additional file 2). The HAAmiRNA site 1 and site 1* region overlaps and is complementary to the predicted #4 microRNA precursor previously described by Bennasser, et al[30], and is bordered by one of the most variable regions in the HIV-1 LTR called the most frequent naturally-occurring length polymorphism (MFNLP) [106]. Conservation of a precursor microRNA would be expected to be in balance with the viral need to escape host RNA silencing mechanisms. The endogenous siRNA produced by the virus, however, mutates along with the viral template. This suggests that selection pressure has maintained the microRNA sites as essential for the virus. Even more interesting is that the precursor microRNA 1 hairpin is entirely deleted/mutated in a group of long-term survivors, who continued with T cell function for longer than expected[108]. If, as suggested in this paper, this particular site targets the human IL-2RG (common gamma chain) mRNA and IL-15 mRNA, and can be shown to impact on T-cell and NK-cell function, this must be taken into consideration when designing vectors for gene therapy. Care must be taken to remove these HAAmiRNA sites or alter their function, if introducing the HIV-1 LTR into susceptible cells. Alternatively, specifically targeting these sites with siRNAs that eliminate their function without perpetuating any genetic damage to the host might be considered. Conclusion RNA silencing for regulation of gene expression is now recognized as an important tool for many species, including humans, to control how and when proteins are made. Viruses have undoubtedly already developed mechanisms that allow them to survive in their host mammalian cell, including subversion of the host cell machinery for RNA silencing. HIV encodes, within its long terminal repeat, an antisense gene responsible for RNA and protein products[14]. The antisense RNA transcribed from this gene can generate an intrinsic, perfectly complementary RNA that base-pairs to the beginning and end portion of the genomic HIV RNA and mRNAs for the viral proteins. Double-stranded RNA initiates RNAi and could allow intrinsic HIV control of when viral RNAs are made. In addition, the antisense RNA forms an intrinsic, intramolecular duplex RNA consistent with microRNA precursor stem-loops. Precursor microRNA stem-loops have already been proposed for the sense HIV-1 RNA[17,18,29,30]. The individual human cellular mRNAs potentially targeted by a single-stranded short RNA (miRNA) derived from this HIV precursor RNA structure turn out to be mRNAs very important in the human adaptive (and innate) immune response. One of the (many) targets of the HIVaINR antisense RNA miRNAs (HAAmiRNAs) is the human interleukin-2 receptor gamma chain, also known as the gamma common chain because it is a component of 6 separate cytokine receptors important in immune cell signalling and interactions. By this mechanism, I propose the human immunodeficiency virus has found a way to cripple effective host cell immune responses. In designing HIV vaccines, this must be taken into account, because incorporation of this HIV antisense gene segment could functionally impair, rather than build an effective immune response. Alternatively, designing gene therapy that targets this HAAmiRNA encoding gene segment, before it gets to the CD4+ T cell, might change the balance of power between virus and human host. Competing interests The author declares that they have no competing interests. Authors' contributions LBL accepts full responsibility for the observations/opinions stated herein. Additional file 1 Click here for file(268K, pdf) Additional file 2 HIVaINR antisense RNA [14] and predicted HAAmiRNAs at sites 1, 2 and 3 (backward yellow arrows) are shown above the corresponding complementary sequence in the HIV-1 sequence alignments for group M (strains A, B, C, D, F1, G, H, J and K), group N, and group O, as well as chimpanzee (CPZ) strains in the long terminal repeat (LTR), as obtained from the HIV Sequence Compendium 2000[107]. HAAmiRNA 3 overlaps and is partially complementary to the nef microRNA:miR-N367 described by Omoto, S., et al., [29] and HAAmiRNA 1 and precursor (pre-HAAmiRNA 1) overlaps and is complementary sequence to the predicted #4 microRNA precursor described by Bennasser, Y. et al [30]. Predicted seed regions for the microRNAs are shaded, and sequence targeting human mRNA is underlined. The B clade HXB2 is the reference sequence, with identical sequences in the strains below, unless otherwise indicated [107]. Click here for file(116K, pdf) Acknowledgements My gratitude to family and friends, who have been supportive (and listened to) this story for over a decade. My thanks also to Rachel Dvoretsky, who contributed artwork for Figures Figures22 References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||
Cell. 1993 Dec 3; 75(5):843-54.
[Cell. 1993]Cell. 1993 Dec 3; 75(5):855-62.
[Cell. 1993]Nature. 2000 Feb 24; 403(6772):901-6.
[Nature. 2000]Nature. 2000 Nov 2; 408(6808):86-9.
[Nature. 2000]Dev Biol. 1999 Dec 15; 216(2):671-80.
[Dev Biol. 1999]Cell. 1985 Jul; 41(3):813-23.
[Cell. 1985]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]J Virol. 1992 Jul; 66(7):4488-96.
[J Virol. 1992]Genes Dev. 1990 Dec; 4(12A):2061-74.
[Genes Dev. 1990]BMC Mol Biol. 2007 Jul 30; 8():63.
[BMC Mol Biol. 2007]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Nature. 2000 Mar 16; 404(6775):293-6.
[Nature. 2000]Nature. 2004 Sep 16; 431(7006):343-9.
[Nature. 2004]Genes Dev. 2001 Jan 15; 15(2):188-200.
[Genes Dev. 2001]EMBO J. 2001 Dec 3; 20(23):6877-88.
[EMBO J. 2001]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Proc Natl Acad Sci U S A. 1986 Jul; 83(14):5000-4.
[Proc Natl Acad Sci U S A. 1986]Science. 2001 Oct 26; 294(5543):862-4.
[Science. 2001]Science. 2001 Oct 26; 294(5543):858-62.
[Science. 2001]Science. 2001 Oct 26; 294(5543):853-8.
[Science. 2001]Nucleic Acids Res. 2005 Jul 1; 33(Web Server issue):W577-81.
[Nucleic Acids Res. 2005]Nature. 2003 Sep 25; 425(6956):415-9.
[Nature. 2003]Curr Biol. 2004 Dec 14; 14(23):2162-7.
[Curr Biol. 2004]Cell. 2004 Jan 23; 116(2):281-97.
[Cell. 2004]Cell. 2006 Jun 2; 125(5):887-901.
[Cell. 2006]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Nucleic Acids Res. 2005 Jul 1; 33(Web Server issue):W577-81.
[Nucleic Acids Res. 2005]RNA. 2007 Apr; 13(4):457-62.
[RNA. 2007]Proc IEEE Comput Soc Bioinform Conf. 2003; 2():159-68.
[Proc IEEE Comput Soc Bioinform Conf. 2003]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]PLoS Biol. 2004 Nov; 2(11):e363.
[PLoS Biol. 2004]Proc Natl Acad Sci U S A. 2006 Aug 15; 103(33):12481-6.
[Proc Natl Acad Sci U S A. 2006]Nucleic Acids Res. 2005 Jul 1; 33(Web Server issue):W577-81.
[Nucleic Acids Res. 2005]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Nucleic Acids Res. 2005 Jul 1; 33(Web Server issue):W577-81.
[Nucleic Acids Res. 2005]RNA. 2007 Apr; 13(4):457-62.
[RNA. 2007]Genes Dev. 2004 Mar 1; 18(5):504-11.
[Genes Dev. 2004]Cell. 2004 Jan 23; 116(2):281-97.
[Cell. 2004]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Genes Dev. 2004 Mar 1; 18(5):504-11.
[Genes Dev. 2004]Nature. 2005 Feb 17; 433(7027):769-73.
[Nature. 2005]Genes Dev. 2003 Feb 15; 17(4):438-42.
[Genes Dev. 2003]PLoS Biol. 2004 Nov; 2(11):e363.
[PLoS Biol. 2004]J Exp Med. 2000 Mar 6; 191(5):771-80.
[J Exp Med. 2000]J Immunol. 2005 Feb 1; 174(3):1213-21.
[J Immunol. 2005]J Exp Med. 1995 Apr 1; 181(4):1519-26.
[J Exp Med. 1995]Immunity. 1998 Nov; 9(5):669-76.
[Immunity. 1998]Nature. 2000 Nov 2; 408(6808):57-63.
[Nature. 2000]EMBO J. 1994 Jun 15; 13(12):2822-30.
[EMBO J. 1994]Cell. 1993 Apr 9; 73(1):147-57.
[Cell. 1993]Am J Hum Genet. 1995 Sep; 57(3):564-71.
[Am J Hum Genet. 1995]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Immunol Lett. 2007 Nov 30; 114(1):1-8.
[Immunol Lett. 2007]EMBO J. 1994 Jun 15; 13(12):2822-30.
[EMBO J. 1994]J Biol Chem. 2002 Apr 5; 277(14):12047-52.
[J Biol Chem. 2002]Nature. 2000 Nov 2; 408(6808):57-63.
[Nature. 2000]Science. 1993 Dec 17; 262(5141):1877-80.
[Science. 1993]Nature. 2000 Nov 2; 408(6808):57-63.
[Nature. 2000]Am J Hum Genet. 1995 Sep; 57(3):564-71.
[Am J Hum Genet. 1995]Scand J Immunol. 2001 Dec; 54(6):582-91.
[Scand J Immunol. 2001]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Retrovirology. 2004 Dec 15; 1():44.
[Retrovirology. 2004]Retrovirology. 2004 Dec 15; 1():43.
[Retrovirology. 2004]RNA. 2007 Apr; 13(4):457-62.
[RNA. 2007]Nucleic Acids Res. 2005 Jul 1; 33(Web Server issue):W577-81.
[Nucleic Acids Res. 2005]Genes Dev. 2004 Mar 1; 18(5):504-11.
[Genes Dev. 2004]PLoS Biol. 2004 Nov; 2(11):e363.
[PLoS Biol. 2004]Neuron. 2003 Feb 20; 37(4):555-8.
[Neuron. 2003]Neuron. 2003 Feb 6; 37(3):417-31.
[Neuron. 2003]Nat Neurosci. 2004 Feb; 7(2):113-7.
[Nat Neurosci. 2004]Genes Dev. 2002 Oct 1; 16(19):2497-508.
[Genes Dev. 2002]Retrovirology. 2004 Dec 15; 1():43.
[Retrovirology. 2004]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Proc Natl Acad Sci U S A. 2006 Aug 15; 103(33):12481-6.
[Proc Natl Acad Sci U S A. 2006]PLoS Biol. 2004 Nov; 2(11):e363.
[PLoS Biol. 2004]Curr Biol. 2005 Jun 21; 15(12):R458-60.
[Curr Biol. 2005]Proc Natl Acad Sci U S A. 2006 Aug 15; 103(33):12481-6.
[Proc Natl Acad Sci U S A. 2006]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Nature. 1987 Apr 16-22; 326(6114):711-3.
[Nature. 1987]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Nature. 2004 Sep 16; 431(7006):343-9.
[Nature. 2004]Proc Natl Acad Sci U S A. 1998 Nov 10; 95(23):13959-64.
[Proc Natl Acad Sci U S A. 1998]Trends Genet. 2001 Aug; 17(8):449-59.
[Trends Genet. 2001]Immunity. 2005 May; 22(5):607-19.
[Immunity. 2005]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Cell. 2002 Sep 6; 110(5):563-74.
[Cell. 2002]Nature. 2003 Sep 25; 425(6956):415-9.
[Nature. 2003]EMBO J. 2002 Sep 2; 21(17):4663-70.
[EMBO J. 2002]Genes Dev. 2004 Dec 15; 18(24):3016-27.
[Genes Dev. 2004]Cell. 2006 Jun 2; 125(5):887-901.
[Cell. 2006]Nucleic Acids Res. 2003 Nov 15; 31(22):6593-7.
[Nucleic Acids Res. 2003]Immunity. 2005 May; 22(5):607-19.
[Immunity. 2005]Trends Genet. 2001 Aug; 17(8):449-59.
[Trends Genet. 2001]Nature. 2003 Dec 18; 426(6968):874-8.
[Nature. 2003]Virus Res. 2004 Jun 1; 102(1):97-108.
[Virus Res. 2004]Nucleic Acids Res. 2005; 33(2):796-804.
[Nucleic Acids Res. 2005]Retrovirology. 2004 Dec 15; 1():43.
[Retrovirology. 2004]Science. 1995 Nov 10; 270(5238):988-91.
[Science. 1995]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]BMC Mol Biol. 2007 Jul 30; 8():63.
[BMC Mol Biol. 2007]Nucleic Acids Res. 2008 Apr; 36(7):2353-65.
[Nucleic Acids Res. 2008]Retrovirology. 2004 Dec 15; 1():44.
[Retrovirology. 2004]Retrovirology. 2004 Dec 15; 1():43.
[Retrovirology. 2004]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Nucleic Acids Res. 2005 Jul 1; 33(Web Server issue):W577-81.
[Nucleic Acids Res. 2005]Retrovirology. 2006 Nov 8; 3():80.
[Retrovirology. 2006]Retrovirology. 2004 Dec 15; 1():44.
[Retrovirology. 2004]Retrovirology. 2004 Dec 15; 1():43.
[Retrovirology. 2004]